(R)-(1-isopropylpyrrolidin-2-yl)methanamine | 1378378-32-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 英文名称: (R)-(1-isopropylpyrrolidin-2-yl)methanamine
• 英文别名: [(2R)-1-(propan-2-yl)pyrrolidin-2-yl]methanamine；[(2R)-1-propan-2-ylpyrrolidin-2-yl]methanamine
• CAS: 1378378-32-5
• 化学式: C₈H₁₈N₂
• mdl: MFCD04114072
• 分子量: 142.244
• InChiKey: GDRVIRMOAGAAGC-MRVPVSSYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  对溴氯甲酸苯酯 、 (R)-(1-isopropylpyrrolidin-2-yl)methanamine 在 三乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 2.0h， 以3%的产率得到4-bromophenyl ((R)-1-isopropylpyrrolidin-2-yl)methylcarbamate trifluoroacetate
  参考文献：
  名称：

  Synthesis and Nicotinic Receptor Activity of Chemical Space Analogues of N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide (PNU-282,987) and 1,4-Diazabicyclo[3.2.2]nonane-4-carboxylic Acid 4-Bromophenyl Ester (SSR180711)

  摘要：

  The Chemical Universe Generated Databases up to 11 atoms of CNOF (GDB-11) and up to 13 atoms of CNOClS (GDB-13) were used to enumerate analogues of the diamine part of two known alpha 7 nicotinic receptor agonists and construct libraries of virtual analogues of these drugs. The libraries were scored using structure-based (docking to the nicotine binding site of the acetylcholine binding protein 1uw6.pdb) or ligand-based (similarity to the parent drugs) methods, and the top-scoring virtual ligands were inspected for easily accessible synthetic targets. In total, 21 diamines were prepared and acylated with aromatic carboxylic or oxycarbonic acids to produce 85 analogues of the parent drugs. The compounds were profiled by electrophysiology in Xenopus oocytes expressing human nicotinic acetylcholine receptor (nAChR) subtypes alpha 7, alpha 3 beta 2, alpha 4 beta 2, alpha 3 beta 4, or alpha 4 beta 4. Characterization of selected compounds revealed eight inhibitors of the alpha 7 nicotinic receptor and three positive allosteric modulators of the alpha 3 beta 2 nAChR.

  DOI：

  10.1021/jm300030r
• 作为产物：
  描述：

  (R)-methyl 1-isopropylpyrrolidine-2-carboxylate 在 lithium aluminium tetrahydride 、 氨 作用下， 以 四氢呋喃 、 乙醚 、 水 为溶剂， 反应 36.0h， 生成 (R)-(1-isopropylpyrrolidin-2-yl)methanamine
  参考文献：
  名称：

  Synthesis and Nicotinic Receptor Activity of Chemical Space Analogues of N-(3R)-1-Azabicyclo[2.2.2]oct-3-yl-4-chlorobenzamide (PNU-282,987) and 1,4-Diazabicyclo[3.2.2]nonane-4-carboxylic Acid 4-Bromophenyl Ester (SSR180711)

  摘要：

  The Chemical Universe Generated Databases up to 11 atoms of CNOF (GDB-11) and up to 13 atoms of CNOClS (GDB-13) were used to enumerate analogues of the diamine part of two known alpha 7 nicotinic receptor agonists and construct libraries of virtual analogues of these drugs. The libraries were scored using structure-based (docking to the nicotine binding site of the acetylcholine binding protein 1uw6.pdb) or ligand-based (similarity to the parent drugs) methods, and the top-scoring virtual ligands were inspected for easily accessible synthetic targets. In total, 21 diamines were prepared and acylated with aromatic carboxylic or oxycarbonic acids to produce 85 analogues of the parent drugs. The compounds were profiled by electrophysiology in Xenopus oocytes expressing human nicotinic acetylcholine receptor (nAChR) subtypes alpha 7, alpha 3 beta 2, alpha 4 beta 2, alpha 3 beta 4, or alpha 4 beta 4. Characterization of selected compounds revealed eight inhibitors of the alpha 7 nicotinic receptor and three positive allosteric modulators of the alpha 3 beta 2 nAChR.

  DOI：

  10.1021/jm300030r

文献信息

• HETEROCYCLIC COMPOUNDS AS JANUS KINASE INHIBITORS
  申请人：Babu Yarlagadda S.

  公开号：US20120309773A1

  公开（公告）日：2012-12-06

  The invention provides compounds of formula I: or a salt thereof as described herein. The invention also provides pharmaceutical compositions comprising a compound of formula I, processes for preparing compounds of formula I, intermediates useful for preparing compounds of formula I, and therapeutic methods for suppressing an immune response or treating cancer or a hematologic malignancy using compounds of formula I.

  本发明提供公式I的化合物：或其盐，如本文所述。本发明还提供包含公式I化合物的药物组合物，制备公式I化合物的方法，用于抑制免疫反应或治疗癌症或血液恶性肿瘤的治疗方法，使用公式I化合物的中间体有助于制备公式I化合物。
• [EN] KRAS MODULATORS AND USES THEREOF<br/>[FR] MODULATEURS DE KRAS ET LEURS UTILISATIONS
  申请人：QUANTA THERAPEUTICS INC

  公开号：WO2022256459A1

  公开（公告）日：2022-12-08

  Provided herein are KRAS modulating compounds, such as compounds of Formula (I), (II), (III), or (X), or pharmaceutically acceptable salts, solvates, stereoisomers, atom labelled, or tautomers of any of the foregoing, useful for modulating KRAS GD12 and/or other G12 mutants. Pharmaceutical compositions comprising a pharmaceutical agent can be formulated in a manner appropriate for the delivery method by using techniques routinely practiced in the art.

  本文提供了KRAS调节化合物，例如公式（I），（II），（III）或（X）的化合物，或者上述任何一种的药用盐，溶剂化合物，立体异构体，原子标记或互变异构体，可用于调节KRAS GD12和/或其他G12突变体。可以使用艺术中常规使用的技术，以适合传递方法的方式制定含有药物的制药组合物。
• ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I
  申请人：Ogawa Tomoyuki

  公开号：US20090131491A1

  公开（公告）日：2009-05-21

  Disclosed is a compound useful as an inhibitor of 11β-hydroxysteroid dehydrogenase type 1. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is a group of the formula: —C(═O)NR 4 R 5 , (wherein R 4 and R 5 are each independently, hydrogen, optionally substituted alkyl or the like) or a group of the formula: —NR 6 C(═O)R 7 , (wherein R 6 and R 7 are each independently, hydrogen, optionally substituted alkyl or the like), X and Y are each independently —O— or the like, Z is a bond or the like, R 2 is optionally substituted alkyl, optionally substituted alkenyl or the like, R 3 is optionally substituted alkyl, optionally substituted alkenyl or the like.
• HETEROCYCLIC COMPOUNDS HAVING TYPE I 11beta HYDROXYSTEROID DEHYDROGENASE INHIBITORY ACTIVITY
  申请人：Kurose Noriyuki

  公开号：US20090170832A1

  公开（公告）日：2009-07-02

  Disclosed is a compound useful as a type I 11βhydroxysteroid dehydrogenase inhibitor. A compound represented by the formula: a pharmaceutically acceptable salt or solvate thereof, wherein R 1 is optionally substituted alkyl or the like, one of R 2 and R 4 is a group of formula: —Y—R 5 , wherein Y is —O— or the like, R 5 is substituted alkyl (the substituent is optionally substituted cycloalkyl or the like), optionally substituted branched alkyl or the like, the other of R 2 and R 4 is hydrogen or optionally substituted alkyl, R 3 is a group of formula: —C(═O)-Z-R 6 , wherein Z is —NR 7 — or —NR 7 —W—, R 6 is optionally substituted cycloalkyl or the like, R 7 is hydrogen or optionally substituted alkyl, W is optionally substituted alkylene, X is ═N— or the like, with the proviso that compounds wherein R 2 is 2-(morphorino)ethoxy, R 3 is N-(1-adamantyl)carbamoyl and R 1 is benzyl are excluded.
• NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE HAVING 11SS-HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORY ACTIVITY
  申请人：Masuda Koji

  公开号：US20100240659A1

  公开（公告）日：2010-09-23

  Disclosed is a compound which is useful as an 11β-hydroxysteroid dehydrogenase type 1 inhibitor. A compound represented by the formula: , its pharmaceutically acceptable salt, or a solvate thereof, wherein Ring A is a group represented by the formula: Ring B is optionally substituted heteroaryl, provided that optionally substituted isoxazole is excluded, or optionally substituted heterocycle, R 1 is hydrogen or optionally substituted alkyl, R 2 is —OR 5 , —SR 5 , halogen, halogenated alkyl or the like, R 3 is optionally substituted alkyl or the like, R 4 is optionally substituted alkyl or the like, R 5 is optionally substituted alkyl or the like, R 6 is hydrogen or the like, R 7 and R 8 are each independently hydrogen or the like, R 10 and R 11 are each independently hydrogen or the like, R 12 is optionally substituted alkyl or the like, m and p are each independently integer of 1 to 3.